The Pharma Data

NOVEMBER 19, 2020

2010 to 2018 Saw Decrease in Rate of Death for People With HIV. 19, 2020 — From 2010 to 2018, there was a 36.6 Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. percent overall during 2010 to 2018 (from 19.4 Professional. THURSDAY, Nov. 20 issue of the U.S. Bosh, Ph.D., to 8.5).

Treatment 52

Treatment Disease Research 52

SCIENMAG: Medicine & Health

JUNE 16, 2023

CHICAGO—The percent of metabolic associated fatty liver disease (MAFLD), the leading global cause of liver disease, is increasing in U.S. Mexican Americans consistently had the highest percentage of MAFLD, especially in 2018, although the prevalence of increase […]

Disease 65

Disease 65

BioPharma Drive: Drug Pricing

OCTOBER 4, 2024

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Disease 69

Disease Drugs 69

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

Disease 69

Disease Drugs Drug Research Trials 69

BioPharma Drive: Drug Pricing

MARCH 17, 2024

The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

Disease 81

Disease Drugs 81

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

Broad Institute

NOVEMBER 4, 2024

By Lucy Mutz November 4, 2024 Credit: Juliana Sohn Kasper Lage is managing director of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease. The overall goal is to translate genetic findings into biological mechanisms underlying disease that could be targeted with new medicines.

Disease 72

Disease Research Science International 72

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Disease 59

Disease Production FDA Drug Development 59

Drug Target Review

NOVEMBER 1, 2023

2 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 1-5 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 2018 Jun 13;5. 2018 Sep;37(2–3):509–18. Frontiers in Medicine.

Clinical Trials 134

Clinical Trials Small Molecule Trials Disease 134

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? Traditionally, Alzheimer’s disease is diagnosed by clinical examination, medical history and cognitive testing. We believe we are at a breakthrough moment in Alzheimer’s disease research.

Disease 59

Disease Clinical Trials Therapies Science 59

Conversations in Drug Development Trends

FEBRUARY 28, 2023

95% of rare diseases don’t have a treatment approved and won’t anytime soon. Uplifting Athletes As a 501(c)(3) nonprofit, UA harnesses the power of sport and partnerships with patient advocacy groups to fund the researchers developing datasets for rare diseases that have never been studied or understood before.

Clinical Trials 52

Clinical Trials Disease Trials Research 52

The Pharma Data

JANUARY 27, 2021

27, 2021 — Heart disease remains the leading cause of death worldwide, with 18.6 million deaths attributed to cardiovascular disease (CVD) globally in 2019, according to a report from the American Heart Association published online Jan. WEDNESDAY, Jan. 27 in Circulation. Virani, M.D., Virani, M.D., percent from 2010.

Disease 52

Disease Virus Pharmaceuticals 52

The Pharma Data

NOVEMBER 14, 2020

14, 2020 — Vaping significantly increases the risk of lung disease, according to a new study that adds to growing evidence that e-cigarettes are dangerous. SATURDAY, Nov. Researchers from Boston University analyzed data gathered from more than 21,600 U.S.

Disease 52

Disease Production Research Marketing 52

SCIENMAG: Medicine & Health

JUNE 13, 2023

People who adhere to global Cancer Prevention Recommendations are putting themselves at lower risk of developing the disease, new research confirms. Experts at Newcastle University have reviewed evidence of following the 2018 World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) lifestyle-based recommendations.

Disease 82

Disease Research 82

The Pharma Data

DECEMBER 4, 2020

Alzheimer Disease Tied to Adverse Financial Events. 4, 2020 — Alzheimer disease and related dementias (ADRDs) are associated with adverse financial events years prior to clinical diagnosis, according to a study published online Nov. Professional. FRIDAY, Dec. 30 in JAMA Internal Medicine. Lauren Hersch Nicholas, Ph.D.,

Disease 52

Disease International Treatment Research 52

Advarra

JULY 26, 2022

The 2018 Farm Bill. The 2018 Farm Bill removed hemp from the Controlled Substance Act. Importantly, the 2018 Farm Bill preserved FDA authority to regulate products with cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic (FD&C) Act and Section 351 of the Public Health Service Act.

Regulations 97

Regulations Research FDA FDA Approval 97

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . adults have been diagnosed with dry eye disease, a chronic, episodic, multifactorial disease. It also increases your risk for inflamed cornea, cornea eye disease, corneal ulcers and injuries, and eye infections. .

Disease 52

Disease Treatment FDA FDA Approval 52

Drug Target Review

NOVEMBER 7, 2024

Introduction Therapeutic antibodies have proven to be indispensable medicines for addressing the most debilitating diseases. Agonist antibodies in immunological diseases Agonist antibodies targeting immune checkpoint pathways are increasingly recognised and investigated for their potential in immunological diseases.

Disease 52

Disease Immune Response Regulations Engineering 52

The Pharma Data

DECEMBER 3, 2020

3, 2020 (American Heart Association News) — Your chances of dying from heart disease or stroke are higher if you live in a county considered socially vulnerable due to factors such as poverty, crowded housing and poor access to transportation, new research shows. THURSDAY, Dec. More than 1 in 3 U.S.

Disease 52

Disease Research Treatment 52

New Drug Approvals

OCTOBER 12, 2024

Alzheon licensed ALZ-801 from NeuroChem and is developing it for Alzheimer’s disease. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. 2018; 32(9): 849–861. [2]. 2018 Mar;57(3):315-333. 2007 ; Kocis et al., 2016 ; Abushakra et al., Hey JA, et al. Clin Pharmacokinet.

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

LifeSciVC

NOVEMBER 17, 2023

This year we start with a deep dive into the biomedical innovation across our industry – “putting the Big back into Big Pharma” with obesity and Alzheimer’s, and the state of play across other disease areas, industry R&D productivity, and the risks facing the sector. As usual, we close with a brief update on Atlas itself.

Science 96

Science Marketing Production Disease 96

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Bioinformatics 98

Bioinformatics Disease Medical Schools Research 98

Broad Institute

SEPTEMBER 15, 2023

We apply STACI to analyze the spatio-temporal progression of Alzheimer’s disease and identify the associated nuclear morphometric and coupled gene expression features.

Disease 40

Disease 40

KIF1A

MAY 4, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. By talking to groups with these mutations, we may identify other diseases whose patients have KIF1A variants. She once worked at SACELLS Biotechnology Co.

Science 116

Science Medical Schools RNA Research 116

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. 2018 Mar;17(3):167–81. 2018 Dec 11;94(10):390–411. 2018;(136):56573. Using stem cell-derived neurons in drug screening for neurological diseases.

Drugs 111

Drugs FDA Disease Animal Testing 111

Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. Published 2018 Nov 13. 2 It is this complexity that necessitates powerful, targeted combination therapies. Available at: [link] Accessed October 2023. Front Pharmacol.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

PLOS: DNA Science

MARCH 21, 2024

Lenmeldy adds functional genes that encode the enzyme arylsulfatase A (ARSA) to bone marrow stem cells taken from children who have inherited the disease, but haven’t yet developed symptoms, which typically begin around age 2 or 3. Each of their children would face a 1 in 4 chance of inheriting the disease.

Therapies 98

Therapies Clinical Trials DNA Trials 98

PLOS: DNA Science

JUNE 1, 2023

This DNA Science post from 2018 traces the history of the efforts. Peter Marinkovich, MD, director of the Blistering Disease Clinic at Stanford Health Care, calls DEB a devastating disease. A dominant form – DDEB – is less severe, blistering the hands, feet, knees, and elbows. Primary investigator M.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

New Drug Approvals

SEPTEMBER 23, 2024

Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. SCHEME PATENT PTC Therapeutics Inc., Audiol Res. 2020-01-02. 2020-01-02.

Small Molecule 57

Small Molecule RNA DNA Disease 57

The Pharma Data

DECEMBER 1, 2020

In 2018, nearly 11% – 14.3 “Individuals with cardiovascular disease have even higher health care costs, including medication costs, so they have to choose what to prioritize,” said Mahajan, a postdoctoral associate at Yale School of Medicine in New Haven, Connecticut. That was compared with 9.1% million – U.S.

Disease 52

Disease Research International Treatment 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

MAY 5, 2022

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia. At Janssen, we’re creating a future where disease is a thing of the past. About Acute Myeloid Leukemia. About the Janssen Pharmaceutical Companies of Johnson & Johnson.

Disease 52

Disease Clinical Trials Drug Development Pharmaceutical Companies 52

The Pharma Data

JANUARY 26, 2021

26, 2021 — According to 2018 data, one in five people in the United States probably carries a sexually transmitted infection, the U.S. Centers for Disease Control and Prevention says. On any given day in 2018, nearly 68 million people… Source link. TUESDAY, Jan.

Disease 52

Disease 52

Drug Target Review

NOVEMBER 3, 2023

The findings may have implications for our understanding of gastrointestinal diseases and endocrine disorders, as well as pancreatic development and diabetes. Further research This discovery may have implications for understanding gastrointestinal diseases and endocrine disorders. 2018 February 8 [2023 November 1];172(4):650-65.

Research 111

Research Regulations DNA Government 111

The Pharma Data

MARCH 16, 2022

The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease to date Detailed results are expected to be presented later this year.

Trials 52

Trials Disease Hospitals Clinical Trials 52

New Drug Approvals

SEPTEMBER 29, 2024

gingivalis has been called a risk factor for Alzheimer’s disease ( Kanagasingam et al., 2018 ; Ding et al., gingivalis is associated with cardiovascular disease. In aged dogs with periodontal disease, ninety days of COR388 reduced oral bacterial load and gum pathology ( Arastu-Kapur et al., 2017 ; Ilievski et al.,

Small Molecule 62

Small Molecule DNA Disease Trials 62

Drug Target Review

FEBRUARY 28, 2024

Human γδ TCR repertoires in health and disease. Trends Immunol 39(6):446-459 (2018). Nat Commun 9(1):1760 (2018). Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105